J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 4, Number 3, June 2012, pages 167-171

Treatment of Burning Mouth Syndrome With Amisulpride

Tables

**Table 1.** Patient’s Characteristics
Gender (female)	Age	Age at onset	Illness duration at our first time (months)	Previous treatments
Female	56	54	36	Fluoxetine
Female	67	65	34	Paroxetine
Female	65	65	37	Fluoxetine,
Female	73	72	24	Paroxetine
Female	49	48	34	Paroxetine
Female	67	66	18	Paroxetine
Female	58	57	24	Paroxetine
Female	54	53	27	Sertraline
Female	68	66	33	Sertraline
Female	60	59	18	Paroxetine
Female	71	70	25	Sertraline
Female	58	56	34	Fluoxetine
Female	64	63	12	Fluoxetine
Female	71	69	8	Paroxetine
Female	61	61	12	Paroxetine
Female	45	43	14	Paroxetine
Female	54	53	12	Paroxetine
Female	56	53	16	Fluoxetine
Female	65	64	33	Fluoxetine
Female	57	56	24	Fluoxetine
Mean ± SD	60.95 ± 7.57	59.65 ± 7.70	2.75 ± 9.48	Fluoxetine

**Table 2.** Rating VAS, HMA-A, HAM-D Scores (mean ± SD) During Treatment With Amisulpride
Scale	VAS	HAM-A	HAM-D
VAS: Visual Analogue Scale; HAM-A: Hamilton Rate Scale for Anxiety; HAM-D: Hamilton Rate Scale for Depression.
Baseline	8.35 ± 0.67	21.10 ± 1.91	20.80 ± 1.47
Week 2	7.0 ± 0.56	15.20 ± 1.36	14.05 ± 1.93
Week 4	5.85 ± 0.87	3.15 ± 1.69	10.80 ± 2.41
Week 6	3.35 ± 0.58	7.90 ± 1.07	8.60 ± 0.59
Week 8	1.15 ± 0.93	4.85 ± 1.18	6.80 ± 0.76
Week 12	1.15 ± 0.81	6.65 ± 0.67	4.70 ± 1.12
Week 16	1.15 ± 0.87	6.45 ± 0.51	4.70 ± 1.03
Week 20	1.05 ± 0.88	6.60 ± 0.75	4.80 ± 1.19
Week 24	1.05 ± 0.87	6.55 ± 0.68	4.68 ± 0.98